Default company panoramic image
Logo

Savara

Inhaled antibiotic for Methicillin-resistant Staphylococcus aureus (MRSA) infections in Cystic Fibrosis (CF) patients.

  • Stage Product In Development
  • Industry Biotechnology
  • Location United States
  • Currency USD
  • Founded August 2008
  • Employees 5
  • Website savarapharma.com

Company Summary

The company’s lead therapy is dry powder inhalable form of an existing IV antibiotic for the treatment of MRSA in Cystic Fibrosis (CF) patients (and other lung compromised patients). Recent studies have shown that median survival time is shortened for CF patients with MRSA. A Phase 2 trial is now underway and will be completed Q4 2014. Savara intends to exit via IPO or acquisition in 2015.

Team

  • Default avatar
    Rob Neville
    CEO

    Mr. Neville is CEO of Savara. Prior to co-founding Savara, Mr. Neville was founder and CEO of the Austin Technology Incubator-based Evity, Inc., which was acquired by BMC in 2000 for $100M based on a single round of angel funding (40x ROI in 18 moinths).

  • Default avatar
    Taneli Jouhikainen
    COO

    Dr. Jouhikainen is Head of Product Development for Savara responsible for product and platform development. He is a veteran executive in the medical and pharmaceutical industries. During his career, Dr. Jouhikainen has held executive positions with several companies including Interim CEO and Senior Vice President of Product Development at Akela Pharma Inc., President and CEO at Focus Inhalation, Chairman of the Board at Spectrum Medical Sciences.

  • Default avatar
    John Lord
    Head CMC

    Dr. Lord is Head of Pharmaceutical Development at Savara and is responsible for all CMC activities. He has over seventeen years of inhalation product development experience working on products ranging from early formulation to commercial. His experience includes leadership roles at numerous pharmaceutical companies including Rhône-Poulenc Rorer and Nektar Therapeutics, with a focus on pharmaceutical development of inhalation products.

  • Default avatar
    Chris Marich
    Head Business Operations

    Mr. Marich is Head of Business Operations and co-founder of Savara. He has significant experience managing the financial and logistical components of large multi-team projects across numerous industries and geographies including enterprise software and pharmaceutical product development. As co-founder of numerous companies from idea to successful exit, including one to a Fortune 1000 company.

Advisors

  • Default avatar
    Andrews Kurth
    Lawyer
    Unconfirmed
    Default avatar
    Pecan Street Partners
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    CTAN Angel Network
    Unconfirmed
    Default avatar
    Aggie Angel Network
    Unconfirmed
    Default avatar
    Keiretsu Forum
    Unconfirmed
  • Default avatar
    North Texas Angel Network
    Unconfirmed
    Default avatar
    Tech Coast Angels
    Unconfirmed